UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934

 

For the Month of June 2017

 

333-206723
(Commission File Number)

 

P.V. Nano Cell Ltd.

(Exact name of Registrant as specified in its charter)

 

8 Hamasger Street
Migdal Ha’Emek, Israel 2310102

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F  þ  Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

On June 20, 2017, P.V. Nano Cell Ltd. (the “Issuer”) issued a press release announcing that it is cooperating with Merck, a leading science and technology company in healthcare, life science, and performance materials, to develop applications utilizing conductive ink. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

  2  

 

 

Exhibit Index

 

Exhibit No.   Description
99.1   Press Release, dated June 20, 2017

 

  3  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  P.V. Nano Cell Ltd.
   
Date:  June 20, 2017 By:

/s/ Fernando de la Vega

   

Name: Dr. Fernando de la Vega

    Title:   Chief Executive Officer

 

 

4

 

 

PV Nano Cell (PK) (USOTC:PVNNF)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse PV Nano Cell (PK)
PV Nano Cell (PK) (USOTC:PVNNF)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse PV Nano Cell (PK)